04:30 AM EDT, 10/06/2025 (MT Newswires) -- Arvinas ( ARVN ) said Sunday its ARV-102 experimental drug was well tolerated in both healthy volunteers and patients with Parkinson's disease in two phase 1 trials.

The company said ARV-102 was safe at single and multiple doses, and significantly reduced levels of LRRK2 protein, adding that LRRK2 "mutations are a frequent familial cause of Parkinson's disease."

"To our knowledge, this is the first time an investigational LRRK2 therapy has, at 14 days in healthy volunteers, shown effects on distal pathway biomarkers in [cerebrospinal fluid] that are elevated in patients with LRRK2 Parkinson's disease," said John Houston, CEO of Arvinas ( ARVN ).

Arvinas ( ARVN ) said it plans to present multiple-dose data in Parkinson's patients in 2026 and also plans to launch a phase 1b trial in patients with progressive supranuclear palsy in H1 next year.

The company's shares gained more than 11% in premarket activity Monday.